

## Data Sharing Statement

Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for Germline *BRCA*-Mutated Metastatic Pancreatic Cancer. *N Engl J Med*. DOI: 10.1056/NEJMoa1903387.

Question	Authors' Response
Will the data collected for your study be made available to others?	Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca's data sharing policy described at <a href="https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure">https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure</a>
Would you like to offer context for your decision?	—
Which data?	—
Additional information about data	—
How or where can the data be obtained?	—
When will data availability begin?	—
When will data availability end?	—
Will any supporting documents be available?	—
Which supporting documents?	—
Additional information about supporting documents	—
How or where can supporting documents be obtained?	—
When will supporting documents availability begin?	—
When will supporting documents availability end?	—
To whom will data be available?	—
For what type of analysis or purpose?	—
By what mechanism?	—
Any other restrictions?	—
Additional information	—

This statement was posted on June 2, 2019, at NEJM.org.